Ablynx and Novartis extend Nanobody agreement

Ablynx, a Belgian pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins, has extended its drug discovery and development alliance with Novartis for another year.

Ablynx, a Belgian pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins, has extended its drug discovery and development alliance with Novartis for another year.

Under the terms of the agreement, entered into in December 2005, the companies are collaborating to develop Nanobody-based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments. Novartis has exclusive rights to develop and commercialise the Nanobody products resulting from the collaboration.

This agreement was previously extended in December 2007 and, based on the positive progress made, the companies have mutually agreed to extend their alliance for another year.

As part of the collaboration Ablynx receives licence fees and funding for r&d. The company is also eligible for milestone payments and royalties upon commercialisation.

Companies